Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

989
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
989
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

909
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
909
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).

Advances in therapy·2018
Same author

The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?

Primary care diabetes·2018
Same author

Thoughts, Words, Action: The Alma-Ata Declaration to Diabetes Care Transformation.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2018
Same author

Basal Insulin Inadequacy versus Failure - Using Appropriate Terminology.

European endocrinology·2018
Same author

Lessons From LEADER - All-round Leadership.

European endocrinology·2018
Same author

Beta-cell Insufficiency.

European endocrinology·2018
Same journal

Predictors of Altmetric Score in Top-Cited Orthopaedic Articles: A Bibliometric Analysis.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Carbon footprint of waste generated in orthopaedic cases in Pakistan: a pilot descriptive study.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Enhancing quotation accuracy assessment with Chatpdf - a game-changer for a century-old conundrum.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Barriers to implementing simulation-based surgical training for improving quality and safety in developing countries: A short communication.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

Intraoperative Adverse Event Reporting in Gastrointestinal Cancer Surgery: A Narrative Review on the Application of ClassIntra.

JPMA. The Journal of the Pakistan Medical Association·2026
Same journal

The Impact of Mortality and Morbidity Meetings on Quality Improvement and Patient Safety.

JPMA. The Journal of the Pakistan Medical Association·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.9K

Sulfonylureas.

Sanjay Kalra, Yashdeep Gupta

    JPMA. the Journal of the Pakistan Medical Association
    |April 3, 2015
    PubMed
    Summary
    This summary is machine-generated.

    This review details the pharmacology of sulfonylureas, assessing their benefits and drawbacks. It offers guidance for safe, effective use, especially in resource-limited settings.

    More Related Videos

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
    08:03

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

    Published on: June 25, 2017

    20.9K
    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
    05:58

    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

    Published on: June 25, 2019

    8.1K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
    07:30

    Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

    Published on: May 10, 2018

    9.9K
    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
    08:03

    Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

    Published on: June 25, 2017

    20.9K
    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
    05:58

    Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

    Published on: June 25, 2019

    8.1K

    Area of Science:

    • Pharmacology
    • Therapeutics
    • Endocrinology

    Background:

    • Sulfonylureas are a widely used class of oral hypoglycemic agents.
    • Understanding their pharmacology is crucial for effective diabetes management.

    Purpose of the Study:

    • To provide a comprehensive review of sulfonylurea pharmacology.
    • To assess the advantages and limitations of sulfonylureas.
    • To offer guidance on their clinical application.

    Main Methods:

    • Literature review of basic and clinical pharmacology studies.
    • Comparative analysis of different sulfonylurea agents.
    • Assessment of clinical utility in various situations.

    Main Results:

    • Sulfonylureas possess distinct pharmacological profiles.
    • Their efficacy is balanced by potential limitations and side effects.
    • Specific agents show varying utility across different patient profiles.

    Conclusions:

    • Sulfonylureas remain an economical therapeutic option.
    • Pragmatic guidance can enhance safe and effective use.
    • Maximal utilization is achievable, particularly in resource-challenged settings.